Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Antipsychotic Invega Gets Long-Term Treatment Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Schizophrenia therapy is seen as a follow-on to Risperdal.

You may also be interested in...



Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia

User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.

Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia

User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.

AstraZeneca’s Seroquel XR Gets FDA Nod For Once-Daily Treatment Of Schizophrenia

AstraZeneca plans to have the extended-release tablets on the market by late July, firm tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel